Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: An open-label pilot study
Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: An open-label pilot study
复制标题
DOI：
10.1016/j.jsat.2010.08.009
复制
发表时间：
2011-01-01
影响因子：
3.9
通讯作者：
Hurt, Richard D.
中科院分区：
文献类型：
--
作者：
Hays, J. Taylor;Croghan, Ivana T.;Hurt, Richard D.
本研究的目的是获得初步证据，证明在康复的酒精依赖吸烟者中，为期12周的伐尼克兰疗程对7天点流行戒烟的有效性。我们在一项开放标签临床试验中招募了32名从酒精依赖中恢复6个月或更长时间的吸烟者。参与者接受每日两次1毫克的伐尼克林治疗，并接受为期12周的行为咨询。参与者69%为男性，94%为白种人，平均每天吸烟20.3 +/- 5.0支。经过12周的治疗，31%的人在生物化学上证实了7天的点流行戒烟，28%的人在目标戒烟日期后2周延长了戒烟时间。最常见的不良反应是轻度至中度恶心（28%）和睡眠障碍（19%）。无严重不良事件报告。伐尼克兰可能是一种有效的辅助治疗烟草依赖的吸烟者在稳定的恢复从酒精依赖。对这种治疗方法的进一步研究是必要的。(C) 2011爱思唯尔公司版权所有。
The purpose of this study was to obtain preliminary evidence of the efficacy of a 12-week course of varenicline for 7-day point prevalence smoking abstinence among recovering alcohol-dependent smokers. We enrolled 32 smokers with 6 months or more of recovery from alcohol dependence in an open-label clinical trial. Participants received varenicline 1 mg twice daily and 12 weeks of behavioral counseling. Participants were 69% men, 94% Caucasian, and smoking an average of 20.3 +/- 5.0 cigarettes per day. After 12 weeks of treatment, 31% were biochemically confirmed 7-day point prevalence abstinent from smoking and 28% had prolonged smoking abstinence (2 weeks after target quit date onward). The most common adverse effects were mild to moderate nausea (28%) and sleep disturbance (19%). No serious adverse events were reported. Varenicline may be a useful aid for treating tobacco dependence among smokers who are in stable recovery from alcohol dependence. Further study of this treatment is warranted. (C) 2011 Elsevier Inc. All rights reserved.